C1-inhibitor: an anti-inflammatory reagent with therapeutic potential

Bibliography

• MOLLER-EBERHARD HJ: Molecular organization and function of the complement system. Ann. Rev Biochem. (1988) 57:321–347.
   PubMedGoogle Scholar
• •Excellent general review on biochemistry and function of the complement system (not yet including the MBL pathway).
   Google Scholar
• MORGAN BP: Complement - Clinical aspects and relevance to disease 'clition 1). Academic Press, London, UK (1990).
   Google Scholar
• The complement system (Edition 2). Rother U, Till G, Hansch GM (Eds.), Springer, Berlin, Germany (1998).
   Google Scholar
• GADJEVA M, THIEL S, JENSENIUS JC: The mannan-binding-lectin pathway of the innate immune response. Curr. Opin. Immunol (2001) 13:74–78.
   PubMedGoogle Scholar
• ••The most recent review on this latestcomplement activation pathway.
   Google Scholar
• LISZEWSKI MK, FARRIES TC, LUBLIN DM, ROONEY IA, ATKINSON JP: Control of the complement system. Adv. Immunol (1996) 61:201–283.
   PubMed Web of Science ®Google Scholar
• •Good overview on complement regulation.
   Google Scholar
• PETERSEN SV, THIEL S, JENSEN L, VORUP-JENSEN T, KOCH C, JENSENIUS JC: Control of the classical and the MBL pathway of complement activation. Mal Immunol (2000) 37:803–811.
   PubMed Web of Science ®Google Scholar
• DALMASSO A: Complement in the pathophysiology and diagnosis of human diseases. CRC Crit. Rev Chia. Lab. Sci (1986) 24:123–183.
   Web of Science ®Google Scholar
• ••Despite its 'age still a remarkable clinically-oriented complement review.
   Google Scholar
• KIRSCHFINK M: Controlling the complement system in inflammation. Immunopharmacology (1997) 38:51–62.
   PubMed Web of Science ®Google Scholar
• KIRSCHFINK M: Targeting complement in therapy. Immunol Rev (2001) 180 (In Press).
   Google Scholar
• •The most recent review on multiple approaches in therapeutic complement inhibition.
   Google Scholar
• MAKRIDES SC: Therapeutic inhibition of the complement system. Pharmacol Rev (1998) 50:59–87.
   PubMed Web of Science ®Google Scholar
• Therapeutic interventions in the complement system. Lambris JD, Holers VM (Eds.), Humana Press, Totowa, New Jersey, USA (2000).
   Google Scholar
• ••Currently the most comprehensiveoverview on therapeutic complement inhibition.
   Google Scholar
• DICKNEITE G: Influence of Cl-inhibitoron inflammation, edema and shock. Behring Inst. Mitt. (1993) 71:299–305.
   Google Scholar
• KIRSCHFINK M, NORNBERGER W: Cl inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mal Immunol. (1999) 36:225–232.
   PubMedGoogle Scholar
• ASGHAR SS, PASCH MC: Therapeutic inhibition of the complement system. Front. Biosci. (2000) 5:E63–E81
   PubMed Web of Science ®Google Scholar
• CALIEZI C, WUILLEMIN WA, ZEERLEDER S, REDONDO M, EISELE B, HACK CE: Cl-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev (2000) 52:91–112.
   PubMed Web of Science ®Google Scholar
• ••Excellent in-depth information on the therapeutic potential of Cl-inhibitor.
   Google Scholar
• HACK CE: The regulation of Cl activation and its role in disease. In: Therapeutic Interventions in the Complement System. Lambris JD, Holers VM (Eds.), Humana Press, Totowa, New Jersey, USA (2000)33–56.
   Google Scholar
• TOSI M, DUPONCHEL C, BOURGAREL P, COLOMB M, MEO T: Molecular cloning of human Cl inhibitor: sequence homologies with alpha 1-antitrypsin and other members of the serpins superfamily. Gene (1986) 42:265–272.
   PubMedGoogle Scholar
• AULAK KS, DONALDSON VH, COUTINHO M, DAVIS AE, III: Cl-inhibitor: structure/function and biologic role. Behring Inst. 114itt. (1993):204–213.
   Google Scholar
• BOCK SC, SKRIVER K, NIELSEN E et al.: Human Cl inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry (1986) 25:4292–4301.
   PubMed Web of Science ®Google Scholar
• PERKINS SJ: Three-dimensional structure and molecular modelling of Cl- inhibitor. Behring Inst. Mitt. (1993):63–80.
   PubMedGoogle Scholar
• SIM RB, REBOUL A, ARLAUD GJ, VILLIERS CL, COLOMB MG: Interaction of 125I-labelled complement subcomponents C- 1 r and C-is with protease inhibitors in plasma. FEBS Lett. (1979) 97:111–1155.
   PubMed Web of Science ®Google Scholar
• MATSUSHITA M, THIEL S, JENSENIUS JC, TERAI I, FUJITA T: Proteolytic activities of two types of mannose-binding lectin-associated serine protease. j Immunol (2000) 165:2637–2642.
   PubMed Web of Science ®Google Scholar
• FORBES CD, PENSKY J, RATNOFF OD: Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum Cl inactivator. j Lab. Clin. Med. (1970) 76:809–815.
   PubMed Web of Science ®Google Scholar
• RATNOFF OD, PENSKY J, OGSTON D, NAFF GB: The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'lr subcomponent of the first component of complement by serum C'l esterase inhibitor. j Exp. Med. (1969) 129:315–331.
   PubMed Web of Science ®Google Scholar
• •Early report on the multiple targets of Cl-inhibitor beyond Cls.
   Google Scholar
• SCHAPIRA M, DE AGOSTINI A, COLMAN RW: Cl inhibitor: the predominant inhibitor of plasma kallikrein. Meth. Enzymol (1988) 163:179–185.
   PubMed Web of Science ®Google Scholar
• VAN DEN GRAAF A, KOEDAM JA, BOUMA BN: Inactivation of kallikrein in human plasma. j Cilia. Invest. (1983) 71:149–158.
   PubMedGoogle Scholar
• HUISMAN LGM, VAN GRIENSVEN JMT, KLUFT C: On the role of Cl-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb. Haemost. (1995) 73:466–471.
   PubMedGoogle Scholar
• ERIKSSON H, SJOGREN HO: Inhibition of activation of human T lymphocytes by the complement Cl esterase inhibitor. Immunology (1995) 86:304–310.
   PubMedGoogle Scholar
• NISSEN MH, BREGENHOLT S, NORDING JA, CLAESSON MH: Cl-esterase inhibitor blocks T lymphocyte proliferation and cytotoxic T lymphocyte generation in vitro. Int. hominid. (1998) 10:167–173.
   Google Scholar
• •New perspectives of the action of Cl-inhibitor are given.
   Google Scholar
• JIANG H, PILLAI S, RUBY E, HOWARD L, BUTLER WJ, ZHANG H: The presence of a Cl-inhibitor-like molecule (C1-INH- L) on human sperm: its involvement in sperm motility. Am. I Reprod. Irnmunol. (1997) 38:384–390.
   PubMed Web of Science ®Google Scholar
• PILLAI FM, JIANG H, ROUDEBUSH WE, ZHANG H, WAHEBA M: Complement component 1 inhibitor (CI-INH) like protein on murine spermatozoa: anti-Cl-INH inhibits in vitro fertilization. Autoimmunity (1998) 28:69–76.
   PubMed Web of Science ®Google Scholar
• PATSTON PA, GETTINS P, BEECHEM J, SCHAPIRA M: Mechanism of serpin action: evidence that Cl inhibitor functions as a suicide substrate. Biochemistry (1991) 30:8876–8882.
   PubMed Web of Science ®Google Scholar
• PERLMUTTER DH, GLOVER GI, RIVETNA M, SCHASTEEN CS, FALLON RJ: Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc. Natl. Acad. Li. USA (1990) 87:3753–3757.
   PubMed Web of Science ®Google Scholar
• BROWER MS, HARPEL PC: Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and Cl inactivator by human polymorphonuclear leukocyte elastase. Biol. Chem. (1982) 257:9849–9854.
   Google Scholar
• QUASTEL M, HARRISON R, CICARDI M, ALPER CA, ROSEN FS: Behavior in vivo of normal and dysfunctional Cl inhibitor in normal subjects and patients with hereditary angioneurotic edema. Clin. Invest. (1983) 71:1041–1046.
   Google Scholar
• WOO P, LACHMANN PJ, HARRISON RA, AMOS N, COOPER C, ROSEN FS: Simultaneous turnover of normal and dysfunctional Cl inhibitor as a probe of in vivo activation of Cl and contact activatable proteases. Clin. Exp. Immunol (1985) 61:1–8.
   PubMed Web of Science ®Google Scholar
• BRACKERTZ D, ISLER E, KUEPPERS F: Half-life of C IINH in hereditary angioneurotic oedema (HAE). Clin. Allergy (1975) 5:89–94.
   PubMedGoogle Scholar
• AGOSTONI A, CICARDI M, BERGAMASCHINI L, BOCCASSINI G, TUCCI A: Cl-inhibitor concentrate for treatment of hereditary angioedema. N Engl. I Med. (1980) 303:527.
   PubMedGoogle Scholar
• GADEK JE, HOSEA SW, GELFAND JA et al.: Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified Cl inhibitor. N Engl. I Med. (1980) 302:542–546.
   PubMed Web of Science ®Google Scholar
• NUIJENS JH, HUIJBREGTS CC et al:Quantification of plasma factor Xlla-C1-inhibitor and kallikrein- Cl-inhibitor complexes in sepsis. Blood (1988) 72: 1841-1848.
   Google Scholar
• NUIJENS JH, EERENBERG BELMER AJ et al: Proteolytic inactivation of plasma Cl-inhibitor in sepsis. I Clin. Invest. (1989) 84:443–450.
   PubMed Web of Science ®Google Scholar
• CALDWELL EE, ANDREASEN AM, BLIETZ MA et al.: Heparin binding and augmentation of Cl inhibitor activity. Arch. Biochem. Biophys. (1999) 361:215–222.
   PubMedGoogle Scholar
• MAURON T, LAMMLE B, WUILLEMIN WA: Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb. Haemost. (1998) 80:82–86.
   PubMed Web of Science ®Google Scholar
• EDENS RE, LINHARDT RJ, WEILER JM: Heparin is not just an anticoagulant anymore: Six and one-half decades of studies on the ability of heparin to regulate complement activity. In: Complement Today Cruse JM, Lewis RE (Eds.), Karger, Basel, Switzerland (1993):96–120.
   Google Scholar
• DALMASSSO AP, PLATT JL: Potentiation of Cl inhibitor plus heparin in prevention of complement-mediated activation of endothelial cells in a model of xenograft hyperacute rejection. Transpl. Proc. (1994) 26:1246–1247.
   PubMedGoogle Scholar
• FIORANTE P, BANZ Y, MOHACSI PJ et al.: Low molecular weight dextran sulfate prevents complement activation and delays hyperacute rejection in pig-to-human xenotransplantation models. Xenotransplantation (2001) 8:24–35.
   PubMedGoogle Scholar
• DAVIS AE: Cl inhibitor and hereditary angioneurotic edema. Ann. Rev Immunol (1988) 6:595–628.
   PubMed Web of Science ®Google Scholar
• SPATH PJ, WOTHRICH B: Inherited and acquired deficiencies of Cl esterase inhibitor in humans. In: The Complement System. Rother K, Till GO, Hansch GM, (Eds). Springer, Berlin (1998):353–410.
   Google Scholar
• ••Most comprehensive review on Cl-inhibitor deficiencies.
   Google Scholar
• AGOSTONI A, CICARDI M: Hereditary and acquired CI-inhibitor deficiency - biological and clinical characteristics in 235 patients. Medicine (1992) 71:206–215.
   PubMed Web of Science ®Google Scholar
• CICARDI M, AGOSTONI A: Hereditary angioedema. N Engl. I Med. (1996) 334:1666–1667.
   PubMed Web of Science ®Google Scholar
• SCHREIBER AD, ZWEIMAN B, ATKINS P et al: Acquired angioedema with lymphoproliferative disorder: association of Cl inhibitor deficiency with cellular abnormality. Blood (1976) 48:567–580.
   PubMed Web of Science ®Google Scholar
• ALSENZ J, BORK K, LOOS M: Autoantibody-mediated acquired deficiency of Cl inhibitor. N Engl. I Med. (1987) 316:1360–1366.
   PubMed Web of Science ®Google Scholar
• BORK K, WITZKE G: Long-term prophylaxis with Cl-inhibitor (Cl INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired CI-inhibitor deficiency. I Allergy Inimunol (1989) 83:677–682.
   PubMed Web of Science ®Google Scholar
• BORK K. Prospective virus safety follow-upafter therapy with a pasteurized Cl-inhibitor concentrate. Biomed. Progr. (1992) 5:59–61.
   Google Scholar
• CICARDI M, MANNUCCI PM, CASTELLI R, RUMI MG, AGOSTONI A: Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of Cl-inhibitor concentrate. Transfusion (1995) 35:209–212.
   PubMed Web of Science ®Google Scholar
• WAYTES AT, ROSEN FS, FRANK MM: Treatment of hereditary angioedema with a vapor-heated Cl inhibitor concentrate. N Engl. J. Med. (1996) 334:1630–1634.
   PubMed Web of Science ®Google Scholar
• FAYMONVILLE ME, MICHEELS J, BODSON L et al.: Biochemical investigations after burning injury: complement system, protease-antiprotease balance and acute-phase reactants. Burns Incl. Therm. Irg. (1987) 13:26–33.
   PubMedGoogle Scholar
• KOWAL-VERN A, WALENGA JM, SHARP-PUCCI M, HOPPENSTEADT D, GAMELLI RL. Postburn edema and related changes in interleukin-2, leukocytes, platelet activation, endothelin-1, and Cl esterase inhibitor. I Burn Care Rehabil (1997) 18:99–103.
   Google Scholar
• CARVALHO AC, DEMARINIS S, SCOTT CF, SILVER LD, SCHMAIER AH, COLMAN RW: Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. I Lab. Clin. Med. (1988) 112:270–277.
   PubMedGoogle Scholar
• ZILOW G, STURM JA, ROTHER U, KIRSCHFINK M: Complement activation and the prognostic value of C3a in patients at risk of adult respiratory distress syndrome. OM. Exp. Immurrol (1990) 79:151–157.
   PubMedGoogle Scholar
• NORNBERGER W, MICHELMANN I, PETRIK K et al: Activity of Cl esterase inhibitor in patients with vascular leak syndrome after bone marrow transplantation. Ann. Hematol (1993) 67:17–21.
   PubMedGoogle Scholar
• BERLING R, OHLSSON K: Effects of high-dose intraperitoneal aprotinin treatment on complement activation and acute phase response in acute severe pancreatitis.j Castroenterol (1996) 31:702–709.
   PubMedGoogle Scholar
• MIKKONEN R, ARONEN HJ, KIVISAARI L, PIILONEN A, SYRJALA M: Plasma levels of prekallikrein, alpha-2-macroglobulin and CI-esterase inhibitor in patients with urticarial reaction to contrast media. Acta Radial (1997) 38:466–473.
   PubMedGoogle Scholar
• GERLACH M, FOHRE B, KEH D, RIESS H, FALKE KJ, GERLACH H: Global and extended coagulation monitoring during extracorporeal lung assist with heparin-coated systems in ARDS patients. Int. J. Artif Organs (1997) 20:29–36.
   PubMedGoogle Scholar
• THUS LG, HACK CE, STRACK VAN SCHIJNDEL RJ et al: Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. J. Immunol (1990) 144:2419–2424.
   Google Scholar
• SALAT C, HOLLER E, SCHLEUNING M et al: Levels of the terminal complement complex, C3a-desArg and CI-inhibitor in adult patients with capillary leak syndrome following bone marrow transplantation. Ann. Hematol (1995) 71:271–274.
   PubMed Web of Science ®Google Scholar
• ROSENSTEIN M, ETTINGHAUSEN SE, ROSENBERG SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J. Immurrol (1986) 137:1735–1742.
   Google Scholar
• HACK CE, OGILVIE AC, EISELE B, EERENBERG AJ, WAGSTAFF J, THUS LG: C 1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2. Int. Care Med. (1993) 19\(Suppl. 1) :S19–S28
   Google Scholar
• OGILVIE AC, BAARS JW, EERENBERG AJM et al.: A pilot study to evaluate the effects of Cl esterase inhibitor on the toxicity of high-dose interleukin 2. Br. J. Cancer (1994) 69:596–598.
   PubMedGoogle Scholar
• NORNBERGER W, HEYING R, BURDACH S, GOBEL U: Cl esterase inhibitor concentrate for capillary leakage syndrome following bone marrow transplantation. Ann. Hematol (1997) 75:95–101.
   PubMedGoogle Scholar
• HEYING R, NORNBERGER W, SPIEKERKOTTER U, GOBEL U: Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: treatment with recombinant plasminogen activator and Cl-esterase inhibitor concentrate. Bone Marrow Transplant (1998) 21:947–949.
   PubMedGoogle Scholar
• HELLER A, KUNZ M, SAMAKAS A, HAASE M, KIRSCHFINK M, KOCH T: The complement regulators Cl inhibitor and soluble complement receptor 1 attenuate acute lung injury in rabbits. Shock (2000) 13:285–290.
   PubMedGoogle Scholar
• BEAL AL, CERRA FB: Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. JAMA (1994) 271:226–233.
   Google Scholar
• STEVENS JH, O HANLEY E SHAPIRO JM et al.: Effects of anti-05a antibodies on the adult respiratory distress syndrome in septic primates. J. OM. Invest. (1986) 77:1812–1816.
   Google Scholar
• HACK CE, NUIJENS JH, FELT BERSMA RJ et al.: Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am. J. Med. (1989) 86:20–26.
   Google Scholar
• COLMAN RW: The role of plasma proteases in septic shock. N Engl. J. Med. (1989) 320:1207–1209.
   PubMedGoogle Scholar
• SIEBECK M, PHILAPITSCH A, WIESINGER H, WELTER HF: Cl-esterase inhibitor in early septicemia. Frog. CM]. Biol. Res. (1987) 236A:141–147.
   PubMedGoogle Scholar
• NAESS F, ROEISE O, STADAAS JO, AASEN AO: On the value of giving a combination of drugs for the treatment of endotoxaemia in pigs. Eur. I Surg. (1992) 158:95–103.
   PubMedGoogle Scholar
• GUERRERO R, VELASCO F, RODRIGUEZ M et al.: Endotoxin-induced pulmonary dysfunction is prevented by C I- esterase inhibitor. J. CM]. Invest. (1993) 91:2754–2760.
   PubMed Web of Science ®Google Scholar
• ••Experimental study in dogs showing thatCl-inhibitor markedly reduced cardio-pulmonary dysfunction in endotoxic shock highlighting Cl-inhibitor as a potential therapeutic candidate in sepsis.
   Google Scholar
• SCHERER RU, GIEBLER RIVI, SCHMIDT U, PAAR D, KOX WJ: The influence of Cl-esterase inhibitor substitution on coagulation and cardiorespiratory parameters in an endotoxin-induced rabbit model of hypercoagulability. Serail]. Thromb. Hemost. (1996) 22:357–366.
   PubMedGoogle Scholar
• JANSEN PM, EISELE B, DEJONG IW et al.: Effect of Cl inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. Immurrol. (1998) 160:475–484.
   Google Scholar
• ••In a model of E coil septicemia inprimates, Cl-inhibitor markedly reduced activation of the classical complement pathway and the factor XII contact activation as well as synthesis of several cytokines, whereas the haemodynamic changes were not prevented.
   Google Scholar
• GIEBLER R, SCHMIDT U, KOCH S, PETERS J, SCHERER R: Combined antithrombin III and C I-esterase inhibitor treatment decreases intravascular fibrin deposition and attenuates cardiorespiratory impairment in rabbits exposed to Escherichia coil endotoxin. Grit. Care Med. (1999) 27:597–604.
   PubMed Web of Science ®Google Scholar
• SONNTAG J, WAGNER MH, LIU G, VOGEL M, WALKA MM, MAIER RF: Effect of CI-inhibitor in a rat model of necrotizing enterocolitis. Biol. Neonate (1999) 76:235–241.
   PubMedGoogle Scholar
• SCHMIDT W, STENZEL K, GEBHARD MM, MARTIN E, SCHMIDT H: Cl-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery (1999) 125:280–287.
   PubMedGoogle Scholar
• FISCHER MB, PRODEUS NICHOLSON-WELLER A et al.: Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by Cl inhibitor replacement. J. Immurrol. (1997) 159:976–982.
   Google Scholar
• ••Excellent study, suggesting a role for Cl-inhibitor in septicemia in the absence of a functional complement system.
   Google Scholar
• HACK CE, VOERMAN HJ, EISELE B et al.: C I-esterase inhibitor substitution in sepsis [letter]. Lancet (1992) 339:378.
   PubMed Web of Science ®Google Scholar
• NORNBERGER W, GOBEL U, STANNIGEL H, EISELE B, JANSSEN A, DELVOS U: Cl-inhibitor concentrate for sepsis-related capillary leak syndrome. Lancet (1992) 339:990.
   Google Scholar
• FRONHOFFS S, LUYKEN J, STEUER K, HANSIS M, VETTER H, WALGER P: The effect of Cl-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients. Intensive Care Med. (2000) 26:1566–1570.
   PubMed Web of Science ®Google Scholar
• MARX G, NASHAN B, COBAS MM et al.: Septic shock after liver transplantation for Caroli's disease: clinical improvement after treatment with Cl-esterase inhibitor. Intensive Care Med. (1999) 25:1017–1020.
   PubMedGoogle Scholar
• GOODMAN AJ, BIRD NC, JOHNSON AG: Antiprotease capacity in acute pancreatitis. Br. J. Surg. (1986) 73:796–798.
   PubMedGoogle Scholar
• YAMAGUCHI H, KIMURA T, MIMURA K, NAWATA H: Activation of proteases in cerulein-induced pancreatitis. Pancreas (1989) 4:565–571.
   PubMed Web of Science ®Google Scholar
• RUUD TE, AASEN AO, PILLGRAM-LARSEN J, STADAAS JO: Effects on peritoneal proteolysis and hemodynamics of prophylactic infusion with Cl inhibitor in experimental acute pancreatitis. Scand. Castroenterol. (1986) 21:1018–1024.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI H, WEIDENBACH H, LUHRS H, LERCH MM, DICKNEITE G, ADLER G: Combined treatment with Cl esterase inhibitor and antithrombin III improves survival in severe acute experimental pancreatitis. Cut (1997) 40:531–535.
   Google Scholar
• TESTONI PA, CICARDI M, BERGAMASCHINI L et al.: Infusion of Cl-inhibitor plasma concentrate prevents hyperamylasemia induced by endoscopic sphincterotomy. Castroiritest. Enclose. (1995) 42:301–305.
   PubMedGoogle Scholar
• NIEDERAU C, BRINSA R, NIEDERAU M, LUTHEN R, STROHMEYER G, FERRELL LD: Effects of Cl-esterase inhibitor in three models of acute pancreatitis. Int. j Paricreatol. (1995) 17:189–196.
   PubMedGoogle Scholar
• SCHNEIDER DT, NLJRNBERGER W, STANNIGEL H, BONIG H, GOBEL U: Adjuvant treatment of severe acute pancreatitis with Cl esterase inhibitor concentrate after haematopoietic stem cell transplantation. Cut (1999) 45:733–736.
   Google Scholar
• MOLLNES TE, FOSSE E: The complement system in trauma-related and ischemic tissue damage: A brief review. Shock (1994) 2:301–310.
   PubMed Web of Science ®Google Scholar
• KOCHILAS L, CAMPBELL B, SCALIA R, LEFER AM: Beneficial effects of Cl esterase inhibitor in murine traumatic shock. Shock (1997) 8:165–169.
   PubMedGoogle Scholar
• VAN DER STARRE P, SINCLAIR D, DAMEN J, BRUMMELHUIS H: Inhibition of the hypotensive effect of plasma protein solutions by Cl esterase inhibitor. I Thorac. Cardiovasc. Surg. (1980) 79:738–740.
   PubMedGoogle Scholar
• MYTHEN MG, PURDY G, MACKIE IJ, MCNALLY T, WEBB AR, MACHIN SJ: Postoperative multiple organ dysfunction syndrome associated with gut mucosal hypoperfusion, increased neutrophil degranulation and Cl-esterase inhibitor depletion. Br j Ariaesth. (1993) 71:858–863.
   PubMed Web of Science ®Google Scholar
• STIEH J, HARDING P, SCHEEWE J, DUTSCHKE P, KRAMER HH: Capillary leak syndrome after open heart surgery for congenital heart defects: Therapy with Cl-inhibitor. Biomed. Progr. (1996) 9:13–16.
   Google Scholar
• ARZNEIMITTELKOMMISSION DER DEUTSCHEN ARZTESCHAFT: Schwerwiegende Thrombenbildung nach Berinert S. Deutsches Arzteblatt (2000) 97:A1015
   Google Scholar
• WEILER JM, EDENS RE, LINHARDT RJ, KAPELANSKI DP: Heparin and modified heparin inhibit complement activation in vivo. j Immuriol. (1992) 148:3210–3215.
   Google Scholar
• WUILLEMIN WA, TE VH, LUBBERS YT, DE RUIG CP, ELDERING E, HACK CE: Potentiation of Cl inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. Immuriol (1997) 159:1953–1960.
   Google Scholar
• •Interesting in vitro study, showing the potentiating effect of Cl-inhibitor on the classical complement pathway and suggesting its potential value for therapeutic complement inhibition.
   Google Scholar
• KIRSCHFINK M, KOVACS B, MOTTAGHY K: Extracorporeal Circulation - in vivo and in vitro analysis of complement activation by heparin-bonded surfaces. Circ. Shock (1993) 40:221–226.
   PubMedGoogle Scholar
• MOLLNES TE: Biocompatibility: Complement as mediator of tissue damage and as indicator of incompatibility. Exp. Immuriogeriet (1997) 14:24–29.
   Google Scholar
• RADKE A, MOTTAGHY K, GOLDMANN C et al.: Cl inhibitor prevents capillary leakage after thermal trauma. Grit. Care Med. (2000) 28:3224–3232.
   PubMedGoogle Scholar
• JOSTKLEIGREWE F, BRANDT KA, JANSSEN AC: Cl-esterase inhibitor (C1-INH) as adjuvant therapy for septic shock following severe thermal trauma. Ann. Haematol. (1997) 74(Suppl.):A159.
   Google Scholar
• BUERKE M, MUROHARA T, LEFER AM: Cardioprotective effects of a Cl esterase inhibitor in myocardial ischemia and reperfusion. Circulation (1995) 91:393–402.
   PubMed Web of Science ®Google Scholar
• ••In an experimental feline model ofmyocardial ischaemia, evidence is provided that Cl-inhibitor is a possible therapeutic candidate in myocardial infarction.
   Google Scholar
• HORSTICK G, HEIMANN A, GOTZE O et al.: Intracoronary application of Cl esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation (1997) 95:701–708.
   PubMed Web of Science ®Google Scholar
• BUERKE M, PRUFER D, DAHM M, OELERT H, MEYER J, DARIUS H: Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury. Pharmacol Esp. Ther. (1998) 286:429–438.
   PubMed Web of Science ®Google Scholar
• MINNEMA MC, PETERS RJ, DE WINTER R et al.: Activation of clotting factors XI and IX in patients with acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol. (2000) 20:2489–2493.
   Google Scholar
• BAUERNSCHMITT R, BOHRER H, HAGL S: Rescue therapy with Cl-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA. Intensive Care Med. (1998) 24:635–638.
   PubMed Web of Science ®Google Scholar
• DE ZWAAN, KLEINE A, DIRIS J et al: Complement inhibition and myocardial protection in patients with acute myocardial infarction. j Am. Coll. Cardiol (2001) 35(Suppl. A): 312. Abstract.
   Google Scholar
• LEHMANN TG, HEGER M, MUNCH S, KIRSCHFINK M, KLAR E: In vivo microscopy reveals that complement inhibition by Cl-esterase inhibitor reduces ischemiaireperfusion injury in the liver. Transpl. Int. (2000) 13\(Suppl. 1):5547–S550.
   Google Scholar
• HEIMANN A, TAKESHIMA T, HORSTICK G, KEMPSKI O: Cl-esterase inhibitor reduces infarct volume after cortical vein occlusion. Brain Res. (1999) 838:210–213.
   PubMed Web of Science ®Google Scholar
• BALDWIN WM, SAMANIEGOPICOTA M, KASPER EK et al.: Complement deposition in early cardiac transplant biopsies is associated with ischemic injury and subsequent rejection episodes. Transplantation (1999) 68:894–900.
   PubMedGoogle Scholar
• PLATT JL, SAADI S: The role of complement in transplantation. Mal Immune]. (1999) 36:965–971.
   PubMedGoogle Scholar
• •Review on the role of complement in allo-and xenotransplantation
   Google Scholar
• SALVATIERRA A, VELASCO F, RODRIGUEZ M et al: C 1 -esterase inhibitor prevents early pulmonary dysfunction after lung transplantation in the dog. Am. J. Respir: Grit. Care Med. (1997) 155:1147–1154.
   Google Scholar
• KLIMA U, KUTSCHKA I, WARNECKE G et al.: Improved right ventricular function after intracoronary administration of a Cl esterase inhibitor in a right heart transplantation model. Eur. j Cardiatharac. &mg. (2000) 18:321–327.
   PubMed Web of Science ®Google Scholar
• HENTJES B, JANKOWSKI M, VANGEROW B et al: C I -esterase-inhibitor levels in patients with and without reperfusion injury following lung transplantation (LTx). Ann. Haematal (1997) 74(Suppl.):A157.
   Google Scholar
• STROBER M, HAGL C, HIRT SW, CREMER J, HARRINGER W HAVERICH A: Cl-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med. (1999) 25:1315–1318.
   PubMedGoogle Scholar
• •Although case-reports only, the results point to a possible role for Cl-inhibitor to prevent lung transplant rejection.
   Google Scholar
• SAADI S, PLATT JL: Role of complement in xenotransplantation. OM. Exp. Pharmacal Physial (1999) 26:1016–1019.
   PubMedGoogle Scholar
• DALMASSO AP PLATT JL: Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by Cl inhibitor. Transplantation (1993) 56:1171–1176.
   PubMedGoogle Scholar
• HECKL-OSTREICHER B, WOSNIK A, KIRSCHFINK M: Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, Cl inhibitor, and soluble complement receptor type 1. Analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation (1996) 62:1693–1696.
   Google Scholar
• •One of the few reports where the protective effect of several complement inhibitors can be compared in the same experimental design.
   Google Scholar
• DI STEFANO R, FROSINI SCAVUZZO M et al.: Cl-Inh and heparan sulfate can prevent discordant rejection. Transplant Proc. (1994) 26:1172–1173.
   Google Scholar
• FIANE AE, VIDEM V, JOHANSEN HT, MELLBYE OJ, NIELSEN EW, MOLLNES TE: Cl-inhibitor attenuates hyperacute rejection and inhibits complement, leukocyte and platelet activation in an ex vivo pig-to-human perfusion model. Immurropharmacology (1999) 42:231–243.
   PubMedGoogle Scholar
• SOLVIK UO, HARALDSEN G, FIANE AE, BORETTI E, THORSBY E, MOLLNES TE: Cl-inhibitor attenuates human serum induced E-selectin expression of pig aortic endothelial cells. Transplant. Proc. (2001) 33:789–790.
   PubMedGoogle Scholar
• MATSUNAMI K, MIYAGAWA S, YAMADA M, YOSHITATSU M, SHIRAKURA R: A surface-bound form of human Cl esterase inhibitor improves xenograft rejection. Transplantation (2000) 69:749–755.
   PubMed Web of Science ®Google Scholar
• ••A construct of human full-length Cl-inhibitor and a transmembrarte anchor provides a novel approach for protection of hyperacute xenotransplant rejection.
   Google Scholar
• MIKATA S, MIYAGAWA S, IWATA K et al.: Regulation of complement-mediated swine endothelial cell lysis by a surface-bound form of human C4b binding protein. Transplantation (1998) 65:363–368.
   PubMedGoogle Scholar
• CARRINGTON CA, RICHARDS AC, VAN DEN BOGAERDE J, TUCKER AW, WHITE DJG: Complement activation, its consequences, and blockade by gene transfer. World J. Surg. (1997) 21:907–912.
   PubMedGoogle Scholar
• LOGAN JS, SHARMA A: Potential use of genetically modified pigs as organ donors for transplantation into humans. OM. Exp. Pharmacal Physial (1999) 26:1020–1025.
   PubMed Web of Science ®Google Scholar
• BRADT BM, KOLB WP COOPER NR: Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. j Esp. Med. (1998) 188:431–438.
   Google Scholar
• VEERHUIS R, JANSSEN I, HOOZEMANS JJ, DE GROOT CJ, HACK CE, EIKELENBOOM P: Complement Cl-inhibitor expression in Alzheimer's disease. Acta Neurapathal (Berl.) (1998) 96:287–296.
   PubMedGoogle Scholar
• VEERHUIS R, JANSSEN I, DE GROOT CJ, VAN MUISWINKEL FL, HACK CE, EIKELENBOOM P: Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not Cl-inhibitor. Exp. Neural (1999) 160:289–299.
   PubMedGoogle Scholar
• YASOJIMA K, MCGEER EG, MCGEER PL: Complement regulators Cl inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Brain Res. (1999) 833:297–301.
   PubMed Web of Science ®Google Scholar
• ELDERING E, HUIJBREGTS CCM, NUIJENS JH, VERHOEVEN AJ, HACK CE: Recombinant Cl-inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils. Clin. Invest. (1993) 91:1035–1043.
   Google Scholar
• ••Different recombinant variants of thereactive centre loop of Cl-inhibitor were produced which exhibited decreased sensitivity for inactivation by neutrophil elastase without loss of specificity for the target proteases, a possible approach for producing recombinant Cl-inhibitor for therapeutic use.
   Google Scholar
• LAMARK T, INGEBRIGTSEN M, BJORNSTAD C, MELKKO T, MOLLNES TE, NIELSEN EW: Expression of active human Cl inhibitor serpin domain in Escherichia coll. Prot. Expr. PuriE (2001) (In Press).
   Google Scholar